2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1460

Minor Salivary Gland Biopsy and Dry Ocular Tests to Detect Occult Sjögren Syndrome in Patients with Interstitial Pneumonia with Autoimmune Features
Abstract Number: 1909

miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Abstract Number: 2727

Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Abstract Number: 888

Mitochondrial DNA Impact on Joint Degeneration Process Using DMM OA and Spontaneous Aging Conplastic Mice Models
Abstract Number: 1961

Mitochondrial DNA Sub-haplogroup H1 Influences the Risk of Rapidly Progressive Osteoarthritis of the Knee: Data from the Osteoarthritis Initiative
Abstract Number: 2036

Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus
Abstract Number: 119

Mitochondrial Transplantation Suppressed Muscle Inflammation and Improved the Mitochondrial Dysfunction in C Protein-induced Myositis Model
Abstract Number: 1722

Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy
Abstract Number: 1723

Mixed Cryoglobulinaemia Since the Advent of New Direct-acting Antivirals for Hepatitis C Infection: Clinical Characteristics, Etiologies and Biological Features in 679 Patients
Abstract Number: 1108

Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)
Abstract Number: 2286

Mobile Responsive App – Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?
Abstract Number: 2892

Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
Abstract Number: 2215

Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab
Abstract Number: 729

Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2376

Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].